Please ensure Javascript is enabled for purposes of website accessibility
Skip to main content



Under guidance of the FDA, available Monoclonal Antibody treatment is no longer believed to be effective against the circulating strains of COVID-19. The current, dominant circulating strains are of the Omicron variant, subvariants BQ.1 and BQ1.1.

As current monoclonal antibody therapy is not believed to be effective against BQ.1 and BQ1.1, Beebe Healthcare is not currently offering Monoclonal Antibody Therapy for COVID-19. Beebe Healthcare will continue to monitor these recommendations and continue to provide effective treatment to our community as available.